PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
November 6, 2013New England Journal of Medicine889 citationsOpen Access

Dolutegravir plus Abacavir–Lamivudine for the Treatment of HIV-1 Infection

View Full Paper
SWSharon WalmsleyAAAntonio AntelaNCNathan Clumeck

Key Points

  • To compare the safety and effectiveness of dolutegravir combined with abacavir-lamivudine against another regimen.
  • Participants received either dolutegravir plus abacavir-lamivudine or efavirenz-tenofovir DF-emtricitabine for 48 weeks.
  • Trial registered under NCT01263015 for accountability.
  • Comparison was based on safety and effectiveness outcomes.
  • Dolutegravir plus abacavir-lamivudine showed a better safety profile compared to efavirenz-tenofovir DF-emtricitabine.
  • The effectiveness was significantly higher for the dolutegravir regimen through 48 weeks, though specific metrics were not detailed.

Abstract

Dolutegravir plus abacavir-lamivudine had a better safety profile and was more effective through 48 weeks than the regimen with efavirenz-tenofovir DF-emtricitabine. (Funded by ViiV Healthcare; SINGLE ClinicalTrials.gov number, NCT01263015 .).

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Walmsley et al. (2013) studied this question.

synapsesocial.com/papers/69d91df1da3af5b1d0835aa0https://doi.org/10.1056/nejmoa1215541
Ask AI
Helpful
Bookmark
Share
View Full Paper